Castle Biosciences (CSTL) Accumulated Expenses (2018 - 2026)

Castle Biosciences has disclosed Accumulated Expenses across 9 years of filings, most recently posting $26.9 million for Q2 2026.

• In Q2 2026, Accumulated Expenses rose 7.69% year-over-year to $26.9 million; the TTM figure through Jun 2026 stood at $26.9 million (up 7.69% YoY), while the FY2025 annual figure was $38.3 million, up 17.61% from the prior year.
• Accumulated Expenses came in at $26.9 million for Q2 2026 at Castle Biosciences, up from $19.1 million in the prior quarter.
• In the past five years, Accumulated Expenses ranged from a high of $38.3 million in Q4 2025 to a low of $8.6 million in Q1 2022.
• Average Accumulated Expenses over 5 years is $22.4 million, with a median of $21.8 million recorded in 2023.
• Year-over-year, Accumulated Expenses jumped 73.0% in 2022 and climbed 7.02% in 2026.
• Over 5 years, Accumulated Expenses stood at $24.4 million in 2022, then gained by 18.83% to $28.9 million in 2023, then gained by 12.47% to $32.6 million in 2024, then gained by 17.61% to $38.3 million in 2025, then dropped by 29.76% to $26.9 million in 2026.
• Per Business Quant data, the three most recent Accumulated Expenses figures were $26.9 million in Q2 2026, $19.1 million in Q1 2026, and $38.3 million in Q4 2025.